Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jun 24;30(2):114-127.
eCollection 2019 Jun.

How close are miRNAs from clinical practice? A perspective on the diagnostic and therapeutic market

E Bonneau  1 , B Neveu  2 , E Kostantin  3 , G J Tsongalis  4 , V De Guire  2
Affiliations

How close are miRNAs from clinical practice? A perspective on the diagnostic and therapeutic market

E Bonneau et al. EJIFCC. .

Abstract

The discovery of miRNAs in the mid-90s has changed the dogma of gene expression regulation. Currently, miRNAs are the main theme of thousands of publications each year and their involvement in human diseases is everyday more deeply understood. With that being known, what are the actual clinical applications of miRNAs and how far are they truly from the patients? To address this question, we reviewed the miRNA diagnostic and therapeutic market. With many companies developing miRNA panels, the activity is high in the diagnostic area. Some products, notably for thyroid cancer (Interpace Diagnostic), are already available to clinician and covered by major insurance companies. In comparison, the therapeutic market, mainly driven by miRNA mimics and antagomiR products, is less advanced. Miravirsen (produced by Roche/Santaris) and RG-101 (produced by Regulus Therapeutics), designed to treat hepatitis C, are considered the flagship products of this class of future drugs. All of the miRNA-based drugs are currently in clinical trials and none have yet reached the pharmaceutical breakthrough. However, acquisition of miRNA-based companies by major pharmas is sending a positive feedback on their potentials. With multiple initiatives on their way, the next years will definitely be determinant for the miRNA market that is still in his infancy.

Keywords: cancer; diagnosis; drug development; microRNA; therapeutics.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Number of studies published in PubMed per year for: (A) RNA studies; (B) RNA diagnostic and therapeutic studies
Figure 2
Figure 2
Number of studies published in PubMed per year for: (A) miRNA studies and (B) miRNA diagnostic and therapeutic studies
See this image and copyright information in PMC

References

    1. North G. Nobel prizes: chemistry. RNA’s catalytic role. Nature. 1989;341(6243):556. - PubMed
    1. Service RF. Chemistry Nobel. Honors to researchers who probed atomic structure of ribosomes. Science (New York, NY). 2009;326(5951):346-347. - PubMed
    1. Bernards R. [The Nobel Prize in Physiology or Medicine for 2006 for the discovery ofRNA interference]. Nederlands tijdschrift voor geneeskunde. 2006;150(52):2849-2853. - PubMed
    1. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998;391(6669):806-811. - PubMed
    1. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75(5):843-854. - PubMed

LinkOut - more resources